Aglatimagene besadenovec clinical trials
Also written AdV-tk and CAN-2409.
How each study uses aglatimagene besadenovec is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the aglatimagene besadenovec studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2008 (2)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2020 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 3
Candel Therapeutics, Inc. (12) · Huazhong University of Science and Technology (3)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test aglatimagene besadenovec.
- Feb 2027A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene BesadenovecPhase 2 · Candel Therapeutics, Inc.
Studies
Open first, then newest update. How each study uses aglatimagene besadenovec is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene BesadenovecRecruitingPhase 2Candel Therapeutics, Inc.NCT07332000Written as aglatimagene besadenovec + valacyclovir
- Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)RecruitingPhase 3Candel Therapeutics, Inc.NCT07660094Written as Aglatimagene Besadenovec
- CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLCActive, not recruitingPhase 2Candel Therapeutics, Inc.NCT04495153Written as Aglatimagene besadenovec
- Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate CancerActive, not recruitingPhase 3Candel Therapeutics, Inc.NCT01436968Written as Aglatimagene besadenovec + valacyclovir
- Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)Active, not recruitingPhase 2Candel Therapeutics, Inc.NCT02768363Written as aglatimagene besadenovec
- Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung CancerCompletedPhase 1Candel Therapeutics, Inc.NCT03131037Written as CAN-2409 + valacyclovir
- Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant GliomaCompletedPhase 2Candel Therapeutics, Inc.NCT00589875Written as CAN-2409
- Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic AdenocarcinomaActive, not recruitingPhase 2Candel Therapeutics, Inc.NCT02446093Written as Aglatimagene besadenovec
- A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain TumorsCompletedPhase 1Candel Therapeutics, Inc.NCT00634231Written as AdV-tk
- AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)CompletedPhase 1Candel Therapeutics, Inc.NCT00638612Written as AdV-tk
- Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant GliomasCompletedPhase 1Candel Therapeutics, Inc.NCT00751270Written as AdV-tk
- Intrapleural AdV-tk Therapy in Patients With Malignant Pleural EffusionCompletedPhase 1Candel Therapeutics, Inc.NCT01997190Written as AdV-tk + valacyclovir
- Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCCStatus unknownPhase 3Huazhong University of Science and TechnologyNCT03313596Written as ADV-Tk
- Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular CarcinomaCompletedPhase 2Huazhong University of Science and TechnologyNCT02202564Written as ADV-TK
- ADV-TK Improves Outcome of Recurrent High-Grade GliomaCompletedPhase 2Huazhong University of Science and TechnologyNCT00870181Written as ADV-TK/GCV
Given beside what is tested · 1 — aglatimagene besadenovec is usual care or a partner of the new treatment
Codes
What other systems call aglatimagene besadenovec · ClinicalTrials.gg INT015153
- UNII (FDA) 5Z72SSS34WAGLATIMAGENE BESADENOVECOne source FDA
- NCI Thesaurus C73996Aglatimagene BesadenovecOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 5Z72SSS34W | AGLATIMAGENE BESADENOVEC | One source FDA |
| NCI Thesaurus | C73996 | Aglatimagene Besadenovec | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.